STAA - STAAR Surgical Company
B. Riley Wealth Advisors Inc. bought a new stake in STAAR Surgical Company (NASDAQ: STAA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 24,160 shares of the medical instruments supplier's stock, valued at approximately $546,000. A number of other institutional investors
STAAR Surgical Company (âSTAARâ or the âCompanyâ) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company's senior leadership team to capitalize on opportunities th.
That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Markets opened Tuesday on edge as surging oil prices, climbing Treasury yields, and a rejected Iran ceasefire rattled traders heading into the final stretch of Q3. Find out which major names on Wall Street got upgraded, downgraded, or freshly initiated before the opening bell.
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately ne.
On September 23, 2026, Staar Surgical Co (STAA) shares fell by 4.1%, closing at $19.80. The stock has had a turbulent year, trading within a 52-week range of $1
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market. The report examines patient.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.
American Capital Management Inc. purchased a new stake in STAAR Surgical Company (NASDAQ: STAA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 846,659 shares of the medical instruments supplier's stock, valued at approximately $24,291,000. American Capital Management Inc.
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
On August 14, 2026, Staar Surgical Co (STAA) shares rose 3.4% today, bringing the current price to $26.19. The stock has fluctuated within a 52-week range of $1
STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago.